A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study

Neuro-oncology
Michael D PradosNorth American Brain Tumor Consortium

Abstract

The purpose of this study was to determine the response to CPT-11 administered every three weeks to adults with progressive malignant glioma, treated with or without enzyme-inducing antiepileptic drug (EIAED) therapy, at the recommended phase 2 dose determined from a previous phase 1 study. Adult patients age 18 or older with a KPS of 60 or higher who had measurable recurrent grade III anaplastic glioma (AG) or grade IV glioblastoma multiforme (GBM) were eligible. No more than one prior chemotherapy was allowed, either as adjuvant therapy or for recurrent disease. The CPT-11 dose was 350 mg/m(2) i.v. every three weeks in patients not on EIAED and 750 mg/m(2) in patients on EIAED therapy. Patients with stable or responding disease could be treated until tumor progression or a total of 12 months of therapy. The primary end point of the study was to determine whether CPT-11 could significantly delay tumor progression, using the rate of six-month progression-free survival (PFS-6). The trial was sized to be able to discriminate between a 15% and 35% rate for the GBM group alone and between a 20% and 40% rate for the entire cohort. There were 51 eligible patients, including 38 GBM and 13 AG patients, enrolled. The median age was 52 a...Continue Reading

References

May 20, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H S FriedmanL L Miller
Sep 12, 2001·Neuro-oncology·K R HessW K Yung
May 9, 2002·Journal of Neuro-oncology·Marc C Chamberlain
Mar 22, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E RaymondJ P Armand
Feb 11, 2004·Neuro-oncology·Tracy T BatchelorUNKNOWN NABTT CNS Consortium
Feb 11, 2004·Neuro-oncology·Michael D PradosUNKNOWN North American Brain Tumor Consortium study

❮ Previous
Next ❯

Citations

Mar 29, 2011·Cancer Chemotherapy and Pharmacology·Athanassios P Kyritsis, Victor A Levin
Jul 29, 2008·Journal of Neuro-oncology·Camilo E FadulJ Marc Pipas
May 24, 2011·Journal of Neuro-oncology·Tyler J FraumFabio M Iwamoto
Feb 8, 2008·Current Treatment Options in Oncology·David A ReardonJames J Vredenburgh
May 30, 2012·Nature Reviews. Clinical Oncology·Chris JonesDarren Hargrave
Nov 23, 2007·The Cancer Journal·Howard A Fine
Oct 7, 2008·The Cancer Journal·John F de Groot, Wai Kwan Alfred Yung
Feb 2, 2012·Chemotherapy Research and Practice·Eleni Timotheadou
Nov 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Annick DesjardinsJames J Vredenburgh
Dec 31, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Teri N KreislHoward A Fine
Jun 19, 2008·Neuro-oncology·Susan M ChangUNKNOWN North American Brain Tumor Consortium
Jun 26, 2008·Neuro-oncology·Stuart A GrossmanUNKNOWN New Approaches to Brain Tumor Therapy CNS Consortium
Sep 12, 2008·Neuro-oncology·James J VredenburghHenry S Friedman
Jul 10, 2010·OncoTargets and Therapy·Argirios Moustakas, Teri N Kreisl
Apr 7, 2009·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Ronald W MercerMaciej S Lesniak
Dec 14, 2011·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Johannes SchwarzenbergWei Chen
Apr 19, 2011·Clinical Medicine Insights. Oncology·Abhirami VivekanandarajahMarcel Odaimi
May 24, 2011·Clinical Medicine Insights. Oncology·Marc C Chamberlain
Sep 1, 2012·CNS Oncology·Sean A Grimm, Marc C Chamberlain
Jan 18, 2014·Journal of Translational Medicine·Pengfei JiangSantosh Kesari
Apr 29, 2014·Clinical Oncology : a Journal of the Royal College of Radiologists·M AjazA Chalmers
May 29, 2014·Cancer Chemotherapy and Pharmacology·Lauriane GoldwirtChristine Fernandez
Jan 15, 2015·Neurosurgical Focus·Brandyn A Castro, Manish K Aghi
Oct 15, 2014·Neuro-oncology·Benjamin M EllingsonTimothy F Cloughesy
Oct 16, 2014·Neuro-oncology·Howard A Fine
Jan 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sith SathornsumeteeJeremy N Rich
Nov 8, 2008·Current Opinion in Neurology·Antonio M Omuro, Jean-Yves Delattre
Oct 16, 2015·Expert Review of Neurotherapeutics·Omar Abdel-Rahman, Mona Fouad
Nov 26, 2011·Expert Review of Anticancer Therapy·Katsuyuki Shirai, Arnab Chakravarti
May 13, 2014·Expert Review of Anticancer Therapy·Richard M Bambury, Patrick G Morris
Dec 20, 2012·Expert Review of Anticancer Therapy·Olivier L Chinot
Jun 9, 2006·Expert Review of Anticancer Therapy·Jennifer I Stern, Jeffrey J Raizer
Oct 31, 2013·Expert Review of Anticancer Therapy·Zabi Wardak, Kevin S Choe

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved